Olufunmilayo Olopade to In Situ Hybridization, Fluorescence
This is a "connection" page, showing publications Olufunmilayo Olopade has written about In Situ Hybridization, Fluorescence.
Connection Strength
0.734
-
Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res. 2001 Jun; 7(6):1676-82.
Score: 0.187
-
Generation of small insert genomic FISH probes with high signal intensity suitable for deletion mapping. Cytogenet Cell Genet. 1997; 76(3-4):202-5.
Score: 0.138
-
Single-day FISH procedure for paraffin-embedded tissue sections using a microwave oven. Biotechniques. 2005 Sep; 39(3):316, 318, 320.
Score: 0.063
-
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 01 01; 30(1):27-35.
Score: 0.049
-
Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer. 2000 Jun; 28(2):164-72.
Score: 0.044
-
Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer. 1998 May; 22(1):72-8.
Score: 0.038
-
Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood. 1995 Sep 01; 86(5):1931-8.
Score: 0.031
-
Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res. 1995 Mar 01; 55(5):984-8.
Score: 0.030
-
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013 Dec; 34(6):3945-58.
Score: 0.027
-
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92.
Score: 0.025
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.023
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.019
-
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
Score: 0.018
-
MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004 Jan 15; 10(2):499-507.
Score: 0.014
-
Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002 Mar; 112(3):472-81.
Score: 0.012
-
Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res. 1996 Dec; 2(12):1993-8.
Score: 0.009
-
Detection of 9p deletions in leukemia cell lines by interphase fluorescence in situ hybridization with YAC-derived probes. Cancer Genet Cytogenet. 1995 Aug; 83(1):46-55.
Score: 0.008